UMA NOOKA: Open Payments
NPI 1790776573 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,331 in 104 payments from 28 companies in 2025. Trend: 2023 $1,952 · 2024 $2,399 · 2025 $2,331
Food & beverage: $2,331
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 11 | $372 |
| ABBVIE INC. | 20 | $331 |
| Corcept Therapeutics | 8 | $208 |
| Novo Nordisk Inc | 6 | $196 |
| AstraZeneca Pharmaceuticals LP | 4 | $185 |
| PFIZER INC. | 13 | $181 |
| Actelion Pharmaceuticals US, Inc. | 3 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $80 |
| Novartis Pharmaceuticals Corporation | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
Products named: Veozah, Korlym, VRAYLAR, BREZTRI, NURTEC ODT, Ozempic, UPTRAVI, REXULTI.
Industry payments across NE — which companies pay providers there.
